SAN DIEGO, May 24 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN),
developer of advanced diagnostic products, announced today it was issued two
patents from the U.S. Patent and Trademark Office, including U.S. Patent
No. 6,891,154, "Amino Acid Sequence Pattern Matching" and No. 6,893,822,
"Enzymatic modification of a nucleic acid-synthetic binding unit conjugate."
Nanogen's growing portfolio of 128 U.S. patents now includes intellectual
property related to novel biomarker discovery technology and methods of
isolating nucleic acids on a microarray.
"The technology that these patents cover can improve our ability to find
appropriate biomarkers and can improve the use of multiplexing in diagnostics,
helping us to bring valuable diagnostic solutions to the market," said Howard
C. Birndorf, Nanogen's chairman of the board and chief executive officer.
"The amino acid matching technology has been used internally to expedite
protein biomarker discovery, providing Nanogen the potential to identify novel
biomarkers of disease for future diagnostic product development. In addition,
our SBU technology promotes specificity and flexibility in the use of our
The '154 patent relates to software designed for amino acid sequencing
pattern matching and determining the number of possible sequences consistent
with the molecular weight of the amino acid. The essential task of
determining the amino acid sequence of an unknown protein depends on sorting
through a large amount of data generated by a mass spectrometer, which can be
time consuming and difficult. In addition, variables such as noise
filtration, offsets in samples and multiple sample preparation methods can
result in unacceptable readings from several samples. This sequence pattern
matching software is designed to provide a superior method for analyzing a
large amount of data to identify unique amino acid sequences quickly, which is
key to proteomic biomarker discovery. The software was developed by SynX
Pharma, a Nanogen subsidiary.
The '822 patent relates to methods using novel synthetic binding units
(SBUs) with very high specificity and sensitivity, linked to nucleic acids as
primers in a PCR or other nucleic acid amplification and detection reaction.
The SBUs only bind to a very specific complement SBU, which may be on a
microarray chip. The SBU can act similarly to the commonly-used
biotin/strepavidin binding pair but many different SBU pairs can be
synthesized. In a multiplex amplification, unique primers can be paired with
unique SBUs so that upon detection on a microarray, the amplified products
array themselves automatically to bind with a complementary SBU attached to
the array. Alternatively a SBU can be used as a label to detect a specific
nucleic acid. The '822 patent adds to a family of technologies that allows
for novel methods of active construction of arrays of immobilized nucleic
acids utilizing prefabricated arrays of SBUs.
About Nanogen, Inc.
Nanogen's advanced diagnostics provide physicians and patients worldwide
with sophisticated information to predict, diagnose and treat disease.
Research and clinical reference labs use the highly accurate and reliable
NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray
and broad suite of analyte specific reagents to develop diagnostic tests for
variety of diseases. Nanogen also offers a broad portfolio of patented
nucleic acids chemistries and molecular tools that accelerate genomic analysis
and are compatible with many systems. The SynX subsidiary offers a line of
point-of-care diagnostic tests and is building expertise in cardiac related
health conditions. Nanogen's ten years of pioneering research involving
nanotechnology may also have future applications in medical diagnostics,
biowarfare and other industries. For additional information please visit
Nanogen's website at www.nanogen.com.
Nanogen Forward-Looking Statement
This press release contains forward-looking statements that are subject to
risks and uncertainties that could cause actual results to differ materially
from those set forth in the forward-looking statements, including whether
patents owned or licensed by Nanogen will be developed into products, whether
the patents owned by Nanogen offer any protection against competitors with
competing technologies, whether products under development can be successfully
developed and commercialized, whether results reported by our customers or
partners can be identically replicated, and other risks and uncertainties
discussed under the caption "Factors That May Affect Results" and elsewhere in
Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date hereof. Nanogen disclaims any intent or obligation to update these
SOURCE Nanogen, Inc.